Introduction
Platelet-rich plasma (PRP) is a concentration of platelets in a small volume of plasma, which is prepared by centrifuging blood with an anticoagulant [1] . Platelet a-granules contain several growth factors, which are released from the a-granules in response to platelet activation with platelet aggregation inducers. PRP can be obtained from human peripheral blood, and has already been applied to regenerative therapies of some tissues such as skin, bone, or tendon. The therapeutic potential of PRP is believed to be closely related to growth factors contained in PRP including platelet-derived growth factor (PDGF), transforming growth factor-b1 (TGFb1), insulin-like growth factor (IGF), and vascular endothelial growth factor (VEGF) [2] . These growth factors participate in the repair of central nervous system (CNS) injury [3, 4] . Nevertheless, the regeneration effects of PRP on spinal cord injury have not been reported. An organ coculture system involving the brain cortex and the spinal cord was developed from neonatal rats. This coculture system allows the quantitative assessment of axon growth in spinal cord and facilitates the analysis of actors that regulate axonal growth [5] [6] [7] [8] . The aim of this study was to determine the ability of PRP to enhance axonal growth in spinal cord tissues and to identify the growth factors in PRP that contribute toward the regulation of axon growth.
Materials and methods
Our research methods were reviewed and approved by the ethical committee of Hiroshima University.
Platelet-rich plasma isolation
A sample of 200 ml of whole peripheral blood was collected from a healthy adult volunteer into an autologous transfusion bag including an anticoagulant and sodium citrate hydrate (Terumo, Tokyo, Japan). Whole blood was initially centrifuged at 1660 rpm for 5 min. The plasma was decanted up to the red blood cell sediment. The red blood cell fraction was discarded and the plasma was centrifuged at 1450 rpm for 15 min. The platelet pellet accumulates at the bottom and the platelet-poor plasma (PPP) accumulates on top. The PPP was drawn off to separate PRP from PPP. A 10 ml solution of PRP was prepared. The release of platelet products into the supernatant was induced by adding 500 IU human thrombin (Benesis, Osaka, Japan) into 10 ml of PRP.
The PDGF-AB, TGF-b1, IGF-1, and VEGF levels in activated PRP were determined using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) technique, with kits for Human PDGF-AB ELISA Kit (Boster Biological Technology, Fremont, California, USA), Human TGF-b1 (R&D Systems, Minneapolis, Minnesota, USA), Human IGF-1 (R&D Systems), and Human VEGF (R&D Systems).
Organ cocultures of brain and spinal cord
Organ cocultures of the brain cortex and spinal cord were prepared as reported previously [5] [6] [7] [8] . Brains and thoracic spinal cords were collected from Sprague-Dawley rats on postnatal day 3 (P3). The dissected cortex and spinal cord were placed on membranes in 1 ml of a horse serumbased medium in six-well tissue culture plates. The spinal cord pieces were aligned next to the white matter of the cortex the following day (Fig. 1a) . The medium was replaced every 3 days. The cocultures were incubated for up to 14 days under 5% CO 2 at 371C (PRP 0% group). The PRP 5% group received 50 ml of PRP per well in 950 ml of medium just after the cortical tissue and the spinal cord tissue came into contact. The PRP-containing medium was replaced every 3 days. The PRP 10% group received 100 ml of PRP per well in the same manner as the PRP 5% group.
The effects of neutralizing antibodies against PDGF-AB, TGF-b1, IGF-1, or VEGF on axon growth were analyzed after adding 50 ml of PRP per well to confirm the key growth factors for axon growth. Cultures were assigned to the anti-PDGF-AB group, the anti-TGF-b1 group, the anti-IGF-1 group, or the anti-VEGF group, and the neutralizing antibody against each growth factor was added to the cocultures; 5 mg of anti-PDGF antibody (R&D Systems) in 5 ml of PBS was added to 1 ml of medium that contained 50 ml of PRP (anti-PDGF-AB group); 0.4 mg of anti-TGF-b1 antibody (R&D Systems) (anti-TGF-b1 group); 3 mg of anti-IGF-1 antibody (R&D Systems) (anti-IGF-1 group); and 2 mg of anti-VEGF antibody (R&D Systems) (anti-VEGF group). All of these neutralizing antibodies were added to the medium each time PRP-containing medium was added to the cocultures.
Tracing of axon growth
Axonal projections from the cortex to the spinal cord were labeled by anterograde tracing with 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine Perchlorate (DiI; Molecular Probes, Eugene, Oregon, USA). The cocultures were fixed in 4% paraformaldehyde at 41C for 1 day. Small crystals (approximately 150 Â 150 mm) of DiI were placed on the center of the cortex, and the cocultures were incubated in 0.1 M phosphate buffer in a humidified atmosphere with 5% CO 2 at 371C for another 14 days. The numbers of labeled axons passing through a reference line running parallel to the junction between the cortex and the spinal cord at a distance of 500, 1000, and 1500 mm from the junction were counted (Fig. 1b) . We evaluated axonal growth using images that were taken at a magnification of Â 200, at different focal planes (approximately 20 planes), using a BZ-9000 (Keyence, Osaka, Japan). The images were then analyzed using the image analysis software (BZ-II analyzer, Keyence). All fibers crossing the reference line were counted, and the counts were expressed as an average number of axons per culture. Results are expressed as the means±SD. The statistical significance of differences in the parameters was assessed using the Kruskal-Wallis test with the Bonferroni-Dunn test. For all data collections, the experimenters were blinded to the group identities.
Results
Quantitative assessment of growth factors in the platelet-rich plasma
The platelet counts and the levels of growth factors in the PRP and PPP preparations are shown in Tables 1 and 2 . The number of platelets in the PRP was 2.67 Â 10 6 cells/ml. The number of platelets in the PPP was 1.19 Â 10 5 cells/ml. In contrast, the number of platelets in nonconcentrated plasma was 2.36 Â 10 5 cells/ml. The concentration of the platelet in PRP was increased by 11.3-fold ( Table 1 ). The supernatant of activated PRP contained a large amount of PDGF-AB, VEGF, IGF-1, and TGF-b1 ( Table 2 ). The platelet concentration in PRP was more than five times the nonconcentrated plasma, and the supernatant of activated PRP contained high levels of PDGF-AB, VEGF, IGF-1, and TGF-b1. Therefore, the preparation of activated PRP was successful.
Axonal growth in organ cocultures with platelet-rich plasma
The mean numbers of labeled axons that extended 500, 1000, or 1500 mm past the corticospinal junction in the (Figs 2 and 3) . Therefore, the PRP 5% group was used in the next step.
Neutralization of growth factors from platelet-rich plasma
Neutralizing antibodies against each growth factor were added to the cocultures. The mean numbers of labeled axons that extended 500, 1000, or 1500 mm past the corticospinal junction in the anti-PDGF-AB group were 13.4±2.61, 6.08±3.11, and 1.83±1.89 (12 cultures/group), respectively, which were not significantly different from the respective numbers in the PRP 5% group. The mean numbers of labeled axons that extended 500, 1000, or 1500 mm past the corticospinal junction in the anti-TGF-b1 group were 24.9±13.7, 12.9±8.59, and 5.50±4.98 (12 cultures/group), respectively, which were significantly greater than the respective number in the PRP 5% group. The mean numbers of labeled axons that extended 500, 1000, or 1500 mm past the corticospinal junction in the anti-IGF-1 group were 5.50±2.93, 1.83±3.42, and 0.25±0.45 (12 cultures/group), respectively. The mean number of labeled axons in extending 500 mm was significantly less than the respective number in the PRP 5% group. The mean numbers of labeled axons that extended 500, 1000, or 1500 mm past the corticospinal junction in the anti-VEGF group were 4.08±1.56, 0.91±0.90, and 0.25±0.45 (12 cultures/group), respectively. The mean numbers of labeled axons in extending 500 and 1000 mm were significantly less than the respective number in the PRP 5% group (Figs 4 and 5) . IGF, insulin-like growth factor; PDGF, platelet-derived growth factor; PPP, platelet-poor plasma; PRP, platelet-rich plasma; TGF, transforming growth factor; VEGF, vascular endothelial growth factor. The average number of axons in cocultures treated with platelet-rich plasma (PRP). *P < 0.05.
Discussion
This study showed that PRP from human peripheral blood contained a large amount of growth factors including PDGF-AB, VEGF, IGF-1, and TGF-b1, and that the administration of PRP promoted axon growth in organ cocultures. The present study showed that IGF-1 and VEGF from PRP contributed positively toward enhanced axonal growth, but TGF-b1 from PRP regulated axon growth negatively.
To identify the axons that extend from the cortex to the spinal cord, the DiI crystals were injected into the center of brain cortex as reported previously [5] [6] [7] [8] . Although the DiI spread from the site of placement within the slice, the diffusion of DiI was blocked at the junction between the cortex and the spinal cord. The DiI traced only the axons that extended from the cortex to the spinal cord.
The mean numbers of labeled axons in the PRP 5% group and the PRP 10% group were significantly greater than the respective number in the PRP 0% group. Furthermore, there was no significant difference in the number of labeled axons between the PRP 5% group and the PRP 10% group. Preliminary studies used the medium including PRP 20% for the cocultures; however, most organ cocultures in this group were dead (data not shown). These findings suggest that PRP is useful in axon regeneration and that it is necessary to use PRP at the appropriate concentration for successful treatment. Addition of 5% PRP to the medium maximally promoted the proliferation of human adipose-derived stem cells and human dermal fibroblasts, but 20% PRP did not promote proliferation [9] . The reasons for the differences in the concentration of PRP suitable for each cell suggest that the difference in the degree of cell differentiation may influence the sensitivity of PRP to growth factors.
Transplantation of CD133 + cells derived from human peripheral blood promotes axon growth in cocultures of the brain and the spinal cord, and the expression of VEGF mRNA derived from the spinal cord is significantly higher in the CD133 + -treated cultures than in the control cultures. CD133 + cells do not secrete VEGF, but may trigger the upregulation of VEGF mRNA in the spinal cord and promote axonal regeneration [10] . Cheng et al. [11] reported that no myelination occurs in the absence of IGF-1. Kohta et al. [12] reported that rats treated with the anti-TGF-b1 antibody show a mild enhancement in growth and/or preservation of axons in the injured spinal cord caudal to the site of contusion, so that the inhibition of TGF-b1 suppressed glial scar formation and upregulated microglia/macrophage activation after the injury, thus presumably providing a favorable environment for the restoration of the neural network. Enge et al. [13] reported that neuron-specific PDGF-B knockout mice have normal CNS development and a normal response to CNS injury. They failed to show any significant deviation from the normal situation. Although the postmitotic CNS neurons represent a major source of PDGF-B in the adult animal, the role of growth factor at this site still remains unknown. PDGF might have an insignificant effect on regeneration of the CNS.
These findings suggested that VEGF and IGF-1 derived from PRP participate in the axon growth of the spinal cord, and TGF-b1 derived from PRP inhibits the axon growth in the spinal cord.
There are some limitations in this study. It is not clear whether the growth factors from PRP acted on the brain or on the spinal cord. It is difficult to clarify this point because of the fact that the receptors of growth factors that enhanced axon growth, including VEGF and IGF-1, have been reported to be present in both the brain cortex and the spinal cord [3, 14, 15] . In previous studies, although the administration of neurotropic factors markedly enhanced axon growth in cocultures from postnatal day 3 (P3) rats, only a slight enhancement in axon growth has been observed in cocultures from postnatal day 7 (P7) rats. In addition, they also showed mixed-age chimeric cocultures including P3 cortex/P7 spinal cord cocultures and P7 cortex/P3 spinal cord cocultures. Neurotrophins induced moderate axon growth in the P7 cortex/P3 spinal cord cocultures, but only produced minimal growth in the P3 cortex/P7 spinal cord cocultures. These results indicate that the successful enhancement of axon growth in cocultures through the neurotropic factors mainly depends on the spinal cord environment itself [8] . Therefore, VEGF and IGF-1 derived from PRP might have a stronger effect on the spinal cord than the cortex.
In the assessment of axon growth with neutralizing antibodies, neutralizing antibodies might therefore reduce the number of axons through the induction of cell death in the cocultures. Neutralizing antibodies against VEGF or IGF-1 decreased not only the number of axons but also the length of axons. This finding indicates that the suppression of axon growth by neutralizing antibodies against VEGF or IGF-1 is not involved in cell death alone. In addition, the number of axons did not decrease by the neutralizing antibodies against PDGF, but they did increase by neutralizing antibodies against TGF-b1. These findings suggest that neutralizing antibodies might have only a limited effect on cell death in the cocultures. In this study, PRP has the ability to promote axon growth in brain-spinal cord tissues through mechanisms related to VEGF and IGF-1. The administration of VEGF or IGF-1 would also promote axon growth. However, PRP has been used more widely in clinical regenerative therapies than growth factors including VEGF and IGF-1. Therefore, the use of PRP might be more feasible for the clinical application than the direct administration of VEGF or IGF-1. The main advantages of PRP are its safety and its availability and the fact that it is easy to administer.
Conclusion
The present study shows that the PRP promotes corticospinal axon growth through VEGF and IGF-1 in PRP.
